Table 4 Sensitivity analysis 1 of the relationships between both the eGFR at age 88 years and the decrease in the eGFR 3 years before (between age 85 and 88) and total and cardiovascular (CV) mortality
eGFR slope per year between 85 and 88 years in ml/min/1.73 m²/year | |||||
|---|---|---|---|---|---|
>-1 | -1 to -2.99 | -3 to -4.99 | <-5 | ||
eGFR at age 88 > 60 (n=169) | n=128 | n=26 | n=12 | n=3 | |
Overall mortality | 1 (ref) | 1.35 (0.81-2.25) | 2.09 (1.07-4.09) | 2.43 (0.74-8.03) | |
CV mortality | 1 (ref) | 1.12 (0.41-3.08) | 3.16 (1.12-8.90) | 8.99 (2.34-34.60) | |
eGFR at age 88 45-59 (n=147) | n=71 | n=46 | n=21 | n=9 | |
Overall mortality | 1 (ref) | 0.70 (0.43-1.15) | 1.07 (0.56-2.05) | 2.31 (1.06-5.06) | |
CV mortality | 1 (ref) | 0.79 (0.34-1.88) | 0.55 (1.39-2.12) | 2.87 (0.84-9.82) | |
eGFR at age 88 < 45 (n=62) | n=20 | n=21 | n=14 | n=7 | |
Overall mortality | 1 (ref) | 0.60 (0.29-1.23) | 0.48 (0.16-1.40) | 1.77 (0.52-6.10) | |
CV mortality | 1 (ref) | 0.91 (0.34-2.39) | 0.31 (0.04-2.42) | 4.00 (1.04-15.43) | |